Performance evaluation of Panther Fusion SARS-CoV-2 assay for detection of SARS-CoV-2 from deep throat saliva, nasopharyngeal, and lower-respiratory-tract specimens
Testing Method Category
Testing Method - Additional Info
performance evaluation of the Panther Fusion severe acute respiratory syndrome coronavirus 2 (SARS?CoV?2) assay (PF assay) (Hologic, Inc.) in comparison to the TIB?Molbiol LightMix SarbecoV E?gene assay (TIB?Molbiol assay) (TIB?Molbiol) using deep throat saliva (DTS), nasopharyngeal (NP) and lower respiratory tract (LRT) specimens.
PPA: 96.43% (NP), 100% (LRT), 96% (DTS), 97.53% (overall); NPA: 100% (NP), 100% (LRT), 100% (DTS), 100% (overall)
158 samples (142 patients)
The database contains available information from scientific literature that is being updated periodically. Please note that the provided information (as retrieved from analysed papers) is provided only for devices commercially available with CE-IVD mark. Acknowledgements